Fate Therapeutics Inc (FATE)
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune disorders in the United States and other international markets. Its pipeline includes CAR-targeted NK and T-cell product candidates such as FT836, which is in preclinical development for multiple tumor types, and FT522, which is being developed for B-cell lymphoma and autoimmune disease. The company’s CAR T-cell programs include FT819 for systemic lupus erythematosus, FT839 for complex autoimmune diseases, and FT825 for solid tumors. Fate Therapeutics also has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. covering off-the-shelf, iPSC-derived CAR T-cell candidates for solid tumors. Incorporated in 2007, the company is based in San Diego, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-FATE
|
$2.32
|
-10.0% Downside
|
Fair
|
$5.74
|
122.7% Upside
|
Bargain
|
Fair
|
0.0%
|
October 29, 2026
|
2.0x
|
47.6x
|
309.1 M
|
231 M
|
20.0%
|
87.8%
|
-8.0
|
83.9%
|
